U.S. Machinery Stock News

Recent share performance puts PPG Industries (PPG) in focus for investors Recent moves in PPG Industries (PPG) have drawn attention, with the stock showing a 1.4% decline over the past day, a 6.8% gain over the past week, and weaker returns over the past month and past 3 months. See our latest analysis for PPG Industries. At a share price of US$103.82, PPG Industries shows short term momentum with a 7 day share price return of 6.8%. However, longer term total shareholder returns over 1, 3 and...

Northern Trust (NTRS) has drawn closer attention after recent trading, with the share price at $134.99 and negative moves over the day, week, month, and past 3 months prompting fresh comparisons with its fundamentals. See our latest analysis for Northern Trust. While the recent 1 day, 1 month, and 3 month share price returns are negative, the 1 year, 3 year, and 5 year total shareholder returns of 42.45%, 68.52%, and 48.60% suggest longer term momentum has been stronger than the latest...

Denali Therapeutics announced that the U.S. Food and Drug Administration previously granted accelerated approval for AVLAYAH (tividenofusp alfa-eknm), the first biologic specifically engineered to cross the blood-brain barrier, for treating neurologic manifestations of Hunter syndrome in certain pediatric patients. This approval not only introduces a new enzyme replacement therapy for a rare pediatric disease but also validates Denali’s TransportVehicle platform as an FDA-cleared route to...

CBL & Associates Properties, Inc. recently closed a US$176 million floating-rate, non-recourse loan with Beal Bank USA, secured mainly by three lifestyle and open-air centers, as the final step in refinancing its former US$634 million secured term loan. The combined refinancings push the secured debt maturity out to 2031, trim total debt by more than US$33 million, and are expected to improve annual free cash flow by over US$30 million while leaving CBL with an estimated cash balance above...

On March 28, 2026, Arcutis Biotherapeutics presented new INTEGUMENT-INFANT Phase 2 and other ZORYVE data at the American Academy of Dermatology meeting in Denver, highlighting reduced signs and symptoms of atopic dermatitis and favorable safety across infants and young children. The company plans to use these infant trial results to support a supplemental New Drug Application for ZORYVE cream 0.05% in infants, potentially broadening its addressable patient population across age groups and...

CBIZ (CBZ) is back in focus after a federal judge rejected its bid to halt a lawsuit over an allegedly understated valuation of AmeriTex Holdings, allowing full discovery into claimed intentional breaches of duty. See our latest analysis for CBIZ. Despite the legal setback, CBIZ’s share price has struggled for some time, with a 90 day share price return of 50.62% and a 1 year total shareholder return of 65.15%, signaling fading momentum rather than a short term wobble. If this kind of legal...

Arbor Realty Trust, Inc. previously closed a US$762.6 million commercial real estate mortgage loan securitization, issuing about US$674.0 million of investment grade-rated notes and retaining roughly US$88.6 million of subordinate interests, backed primarily by first mortgage bridge loans and featuring a reinvestment period of about two and a half years. The transaction effectively refinances existing borrowings while adding capacity to acquire up to US$100.0 million of additional loans,...

In March 2026, MACOM Technology Solutions Inc. announced new 448G PAM4 modulator drivers and joined Broadcom, Cisco, NVIDIA and Semtech in forming the 400G Optical MSA to define interoperable 400G-per-wavelength interfaces for next-generation AI data center equipment. This combination of higher-speed optical components and participation in an industry standards group positions MACOM at the heart of emerging AI infrastructure connectivity, even as US-China trade tensions add uncertainty for...

GXO Logistics recently opened Hasbro’s new 600,000-square-foot flagship distribution center in Midway, Georgia, and launched its first autonomous industrial truck pilot in Épinoy, France, marking concrete advances in AI-enabled warehouse operations. These moves, underpinned by GXO IQ and collaborations with KION, NVIDIA and Accenture, show how the company is applying emerging automation technologies in real-world logistics networks at scale. We’ll now examine how the rollout of GXO...

Earlier this month, Coeur Mining replaced its 2017 credit agreement with a new five-year, US$1.00 billion senior secured revolving facility, launched a US$400 million bond-exchange offer tied to its New Gold acquisition, updated 2026 gold, silver and copper production guidance, expanded its authorized share count to 1.30 billion, and added Patrick Godin and Marilyn Schonberner to its board. Together, these financing, governance and capital-structure moves point to a company reshaping its...

MoonLake Immunotherapeutics recently reported long-term Week 40 data from its Phase 3 VELA-1 and VELA-2 trials of sonelokimab in moderate-to-severe hidradenitis suppurativa, showing sustained clinical responses, meaningful quality-of-life improvements and a stable safety profile. An especially distinctive takeaway is that sonelokimab reached high rates of deep lesion clearance and inflammatory remission on multiple rigorous HS scoring measures, suggesting a potentially higher treatment bar...

American Assets Trust (AAT) has been drawing attention after recent share performance, with the stock near US$18 and returns over the month and past 3 months tracking in negative territory. See our latest analysis for American Assets Trust. At a share price of US$18.18, American Assets Trust has seen a 6.9% 1 month share price decline and a 3.2% year to date share price decline. The 3 year total shareholder return of 18.0% contrasts with a 28.1% total shareholder return decline over 5 years,...

Why Celldex Therapeutics Is On Investors’ Radar Celldex Therapeutics (CLDX) has recently caught investor attention without a single headline event driving the story. This naturally shifts the focus toward its recent share performance and underlying business profile. See our latest analysis for Celldex Therapeutics. At a share price of $30.30, Celldex Therapeutics has seen a 16.4% 90 day share price return and a 52.0% 1 year total shareholder return. This suggests recent momentum has...

In the past week, O'Reilly Automotive drew attention as it approached its first-quarter earnings release, with analysts forecasting a double-digit adjusted EPS increase and management guiding for comparable store sales growth of 3% to 5% alongside an EPS outlook for 2026 between $3.10 and $3.20. Despite a recent period of weaker share performance and softer quarterly results, O'Reilly continues to post average same-store sales growth of 3.8% per year over the last two years while sustaining...

On March 26, 2026, ADW Capital Management issued an open letter to Driven Brands Holdings’ board urging an immediate strategic review, criticizing governance, capital allocation, and the costly car wash expansion and exit, while calling for independent advisors, overhead cuts, and greater transparency. ADW Capital argues these issues have created a major gap between Driven Brands’ business value and its market valuation, suggesting that a controlled sale or breakup could unlock materially...

Why United Airlines Holdings Stock Is On Investors’ Radar Without a clear single news catalyst, United Airlines Holdings (UAL) is drawing attention after a run of mixed returns, with gains over the past year but weaker performance in the month and past 3 months. See our latest analysis for United Airlines Holdings. At a share price of $88.44, United Airlines Holdings has seen a 30 day share price return of 16.8% and a year to date share price return of 21.74% decline, while its 1 year total...

What Recent Performance Says About First Industrial Realty Trust First Industrial Realty Trust (FR) has drawn attention after a recent 1-day decline, along with a 1-month return of about 9% lower and a mild negative move over the past 3 months. For investors watching industrial real estate, the stock's 1-year total return of 10.25% sits next to a value score of 2 and an indicated intrinsic discount of about 15%. Together, these figures may provide an interesting starting point for further...

AeroVironment (AVAV) has put its LOCUST X3 high energy laser system at the center of the story, highlighting AI-enabled drone defense and modular design as a fresh reference point for the stock. See our latest analysis for AeroVironment. Despite the high profile LOCUST X3 launch and recent media attention, AeroVironment’s 30 day share price return of 26.89% and year to date share price return of 28.01% are negative, while its 1 year total shareholder return of 52.51% and 3 year total...

Why United Natural Foods is Back on Investors’ Radar United Natural Foods (UNFI) has attracted fresh attention after recent share price moves, with the stock showing strong gains over the past month and past 3 months. This has prompted investors to reassess the distributor’s current valuation and risk profile. See our latest analysis for United Natural Foods. Those short term gains sit on top of a much stronger longer term picture, with a 37.4% year to date share price return and a 72.0%...

RH (RH) has drawn fresh attention after appointing long-time manufacturing partner executive Veronica Schnitzius to lead manufacturing and sourcing, alongside the return of real estate veteran David Stanchak to oversee expansion and asset monetization. See our latest analysis for RH. Those leadership changes arrive after a sharp reset in investor expectations, with the 30 day share price return of RH at a 21.04% decline and the 1 year total shareholder return down 44.62%. This points to...

Green Plains (GPRE) has drawn fresh attention as investors reassess its role in low carbon fuels, with recent returns over the month and past 3 months prompting closer scrutiny of its fundamentals. See our latest analysis for Green Plains. At a share price of $16.89, Green Plains has seen a 30 day share price return of 23.02% and a 90 day share price return of 71.47%. Its 1 year total shareholder return of 247.53% contrasts with weaker 3 and 5 year total shareholder returns, suggesting strong...

Marex Group plc recently issued earnings guidance for the first quarter ended March 31, 2026, forecasting revenues between US$667 million and US$697 million, compared with US$467 million in the same period of 2025. This guidance implies a sharp year-on-year uplift in expected quarterly revenue, hinting at materially stronger client activity and business momentum across Marex’s platform. We’ll now examine how this significantly higher first-quarter 2026 revenue outlook influences Marex...

In March 2026, Tarsus Pharmaceuticals announced that its partner Grand Pharmaceutical Group secured National Medical Products Administration approval in China for TP-03 (XDEMVY) to treat Demodex blepharitis, triggering a US$15,000,000 milestone payment to Tarsus and confirming TP-03 as the first approved therapy addressing the disease’s root cause in Greater China. This approval not only validates TP-03’s clinical and regulatory profile outside the U.S., but also opens a new revenue stream...

Monte Rosa Therapeutics, Inc. recently reported a fourth-quarter 2025 net loss of US$46.14 million and entered a supply agreement with Johnson & Johnson to evaluate its investigational molecular glue degrader MRT-2359 in combination with ERLEADA in a planned Phase 2 study for metastatic castration-resistant prostate cancer. This collaboration, together with positive early data for MRT-2359 presented at the 2026 ASCO GU Cancers Symposium, highlights growing external interest in Monte Rosa’s...